{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:03:58Z","timestamp":1793160238449,"version":"4.5.0"},"reference-count":37,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"unspecified","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["K23DK118200"],"award-info":[{"award-number":["K23DK118200"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R03DK129558"],"award-info":[{"award-number":["R03DK129558"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001450"],"award-info":[{"award-number":["UL1 TR001450"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2024,6,30]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We aimed to determine the association of statins with progression to a high risk for advanced fibrosis in primary care patients with metabolic dysfunction-associated steatotic liver disease (MASLD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This retrospective cohort study of electronic health record data included patients with MASLD and an initial low or indeterminate risk for advanced fibrosis, determined by Fibrosis-4 Index (FIB-4) score (&lt;2.67). Patients were followed from the index FIB-4 until the primary outcome of a high-risk FIB-4 (\u22652.67) or the end of the study period. Prescription for a statin during follow-up was the primary exposure. We developed Cox regression models for the time to a high-risk FIB-4 score with statin therapy as the primary covariate and adjusting for baseline fibrosis risk, demographic and comorbidity variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort of 1238 patients with MASLD was followed for a mean of 3.3 years, with 47% of patients receiving a prescription for a statin, and 18% of patients progressing to a high-risk FIB-4. In the adjusted Cox model with statin prescription as the primary exposure, statins were associated with a lower risk (HR 0.60; 95% CI 0.45 to 0.80) of progressing to a FIB-4\u22652.67. In the adjusted Cox models with statin prescription intensity as the exposure, moderate (HR 0.60; 95% CI 0.42 to 0.84) and high intensity (HR 0.61; 95% CI 0.42 to 0.88) statins were associated with a lower risk of progressing to a high-risk FIB-4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Statin prescriptions, and specifically moderate and high intensity statin prescriptions, demonstrate a protective association with fibrosis risk progression in primary care patients with MASLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgast-2024-001404","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T14:15:11Z","timestamp":1721225711000},"page":"e001404","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["Statin prescriptions and progression of advanced fibrosis risk in primary care patients with MASLD"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0914-3182","authenticated-orcid":false,"given":"Andrew D","family":"Schreiner","sequence":"first","affiliation":[{"name":"Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsey A","family":"Petz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P","family":"Moran","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G","family":"Koch","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Marsden","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Bays","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick D","family":"Mauldin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulugeta","family":"Gebregziabher","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"2025073012461724000_11.1.e001404.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.13044"},{"key":"2025073012461724000_11.1.e001404.2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000624"},{"key":"2025073012461724000_11.1.e001404.3","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000678"},{"key":"2025073012461724000_11.1.e001404.4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367"},{"key":"2025073012461724000_11.1.e001404.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.05.013"},{"key":"2025073012461724000_11.1.e001404.6","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025073012461724000_11.1.e001404.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.03.010"},{"key":"2025073012461724000_11.1.e001404.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.07.027"},{"key":"2025073012461724000_11.1.e001404.9","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"2025073012461724000_11.1.e001404.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029349"},{"key":"2025073012461724000_11.1.e001404.11","doi-asserted-by":"publisher","DOI":"10.2337\/dci21-0020"},{"key":"2025073012461724000_11.1.e001404.12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2023.100897","article-title":"National study of NAFLD management identifies variation in delivery of care in the UK between 2019 to 2022","volume":"5","author":"Li","year":"2023","journal-title":"JHEP Rep"},{"key":"2025073012461724000_11.1.e001404.13","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S2468-1253(22)00061-9","article-title":"Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the study of the liver and British society of Gastroenterology NAFLD special interest group","volume":"7","author":"McPherson","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025073012461724000_11.1.e001404.14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1210\/clinem\/dgab641","article-title":"Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China","volume":"107","author":"Liang","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2025073012461724000_11.1.e001404.15","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.cgh.2023.04.017","article-title":"Statins are associated with a decreased risk of severe liver disease in individuals with noncirrhotic chronic liver disease","volume":"22","author":"Sharma","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025073012461724000_11.1.e001404.16","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.20222","article-title":"Association of statin use with risk of liver disease, hepatocellular carcinoma, and liver-related mortality","volume":"6","author":"Vell","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025073012461724000_11.1.e001404.17","doi-asserted-by":"crossref","first-page":"154752","DOI":"10.1016\/j.metabol.2021.154752","article-title":"Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes","volume":"121","author":"Ciardullo","year":"2021","journal-title":"Metab Clin Exp"},{"key":"2025073012461724000_11.1.e001404.18","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1007\/s11606-021-07341-z","article-title":"The association of fibrosis-4 index scores with severe liver outcomes in primary care","volume":"37","author":"Schreiner","year":"2022","journal-title":"J Gen Intern Med"},{"key":"2025073012461724000_11.1.e001404.19","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/liv.15295","article-title":"FIB-4 and incident severe liver outcomes in patients with undiagnosed chronic liver disease: a fine-gray competing risk analysis","volume":"43","author":"Schreiner","year":"2023","journal-title":"Liver Int"},{"key":"2025073012461724000_11.1.e001404.20","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s11606-023-08093-8","article-title":"Real-world primary care data comparing ALT and FIB-4 in predicting future severe liver disease outcomes","volume":"38","author":"Schreiner","year":"2023","journal-title":"J Gen Intern Med"},{"key":"2025073012461724000_11.1.e001404.21","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21669"},{"key":"2025073012461724000_11.1.e001404.22","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/hep.31726","article-title":"Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement","volume":"74","author":"Hagstr\u00f6m","year":"2021","journal-title":"Hepatology"},{"key":"2025073012461724000_11.1.e001404.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2009.05.033"},{"key":"2025073012461724000_11.1.e001404.24","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","article-title":"Easl clinical practice guidelines (Cpgs) on non-invasive tests for evaluation of liver disease severity and prognosis- 2020 update","volume":"75","author":"Berzigotti","year":"2021","journal-title":"J Hepatol"},{"key":"2025073012461724000_11.1.e001404.25","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"2025073012461724000_11.1.e001404.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2012.08.007"},{"key":"2025073012461724000_11.1.e001404.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-6773.2007.00822.x"},{"key":"2025073012461724000_11.1.e001404.28","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"2025073012461724000_11.1.e001404.29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/j.gastro.2023.04.025","article-title":"Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study","volume":"165","author":"Huang","year":"2023","journal-title":"Gastroenterology"},{"key":"2025073012461724000_11.1.e001404.30","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000437741.48606.98"},{"key":"2025073012461724000_11.1.e001404.31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.13044"},{"key":"2025073012461724000_11.1.e001404.32","doi-asserted-by":"crossref","first-page":"408","DOI":"10.37765\/ajmc.2023.89406","article-title":"Statin prescribing patterns in patient-centered medical home patients with NAFLD","volume":"29","author":"Cipriani","year":"2023","journal-title":"Am J Manag Care"},{"key":"2025073012461724000_11.1.e001404.33","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322572"},{"key":"2025073012461724000_11.1.e001404.34","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.005"},{"key":"2025073012461724000_11.1.e001404.35","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"2025073012461724000_11.1.e001404.36","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00634-7"},{"key":"2025073012461724000_11.1.e001404.37","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.14309\/ajg.0000000000002098","article-title":"Exercise training is associated with treatment response in liver fat content by magnetic resonance imaging independent of clinically significant body weight loss in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"118","author":"Stine","year":"2023","journal-title":"Am J Gastroenterol"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2024-001404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T19:46:27Z","timestamp":1753904787000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2024-001404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,7,17]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1136\/bmjgast-2024-001404"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2024-001404","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7]]}}}